Difference between actual and published PK parameters [Study As­sess­ment]

posted by Loky do – Egypt, 2022-02-15 14:20 (356 d 15:45 ago) – Posting: # 22783
Views: 1,174

Thanks Helmut for your reply ;-), excuse my confusion, I have a question regarding dapoxetine biphasic half-life; the initial and terminal half-life (the initial half-life which is 1.3-1.5 hours and the terminal half-life which is 15-19 hours) does this biphasic nature affect the practical obtained half life of the drug? and is this nature could affect the drug variability?


Complete thread:

UA Flag
 Admin contact
22,481 posts in 4,710 threads, 1,603 registered users;
22 visitors (0 registered, 22 guests [including 10 identified bots]).
Forum time: 06:05 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz